Introduction
F-box proteins (a family of approximately 70 members in mammals) provide the substrate specificity of SCF (Skp1, Cul1, F-box protein) ubiquitin ligase complexes.
1 Skp2 is the substrate targeting subunit of the SCF ubiquitin ligase that targets the CDK inhibitor p27 and other negative regulators of cell proliferation for proteasomal degradation. 1 In late G 1 , after the cell has committed to the next round of cell division, p27 is eliminated via SCF Skp2 to allow activation of Cdk1 and Cdk2 and, consequently, promote progression through the subsequent phases of the cell cycle. To prevent premature degradation of p27, Skp2 levels are kept low during early-and mid-G 1 due to the APC/C Cdh1 ubiquitin ligase, which mediates the ubiquitylation of Skp2. 2, 3 Skp2 contains two degradation motifs (degrons): the first degron (amino acids 3-6 in human) is a classical APC/C recognition motif (D box), while the second (amino acids 46-94) mediates the stable interaction between Skp2 and the APC/C activator protein Cdh1. 2, 3 The second degron contains a conserved CDK phosphorylation consensus site (Ser64 in human Skp2), which we found to be phosphorylated in endogenous Skp2 (unpublished results), and at least two other potential phosphorylation sites (Ser72 and Ser75). We mutated these three residues to alanine (individually or in combination) to determine their role in the APC/C Cdh1 -mediated degradation of Skp2. While these experiments were in progress, another group showed that phosphorylation of Ser64 and, to a lesser extent, Ser72 of Skp2 contributes to the stabilization of Skp2 by preventing its association with APC/C Cdh1 . 4 Similar conclusions were reached by Gao et al. 5 Furthermore, recently published reports assert that Ser72 phosphorylation by Akt/protein kinase B (PKB) plays an important role in SCF Skp2 assembly and activation 6 and controls the subcellular localization of Skp2. 5, 6 Here, we investigated whether the phosphorylation status of Skp2 affects SCF Skp2 assembly, the binding of Skp2 with known interactors, and Skp2 subcellular localization.
Results and Discussion
We used a panel of Skp2 phosphorylation site mutants and a deletion mutant lacking the first 94 amino acids [Skp2(∆94)].
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(to achieve low expression) with wild type and mutant Skp2 constructs (data not shown). Moreover, treatment of HEK293T cells with LY294002, an inhibitor of the PI(3)K-Akt pathway, did not affect the binding between endogenous Skp2 and either Skp1 or Cul1 (Fig. 2) .
We also measured the in vitro ubiquitylation activity of the Skp2 panel and found that all Skp2 mutants were able to ubiquitylate p27 to an extent indistinguishable from that of wild type Skp2 (Fig. 3) . Accordingly, expression of Skp2 mutants in HEK293T cells promoted the in vivo ubiquitylation of p27 as efficiently as wild type Skp2 (Fig. 4) .
Finally, we examined the subcellular localization of FLAGtagged Skp2(Ser72Ala) and Skp2(Ser72Asp) mutants in HeLa and U-2OS cells using indirect immunofluorescence. Like wild type Skp2, the two mutants were found to localize to the nucleus in 100% of the cells examined ( Fig. 5 and data not shown). Moreover, co-expression of a constitutively active Akt1 FLAG-tagged, wild type Skp2 and different Skp2 mutants were transiently expressed in HEK293T cells, and after lysing the cells, Skp2 was immunoprecipitated using an anti-FLAG antibody. With the exception of Skp2(∆94), which, as previously reported, 7 did not bind to the cyclin A-Cdk2 complex, the different Skp2 constructs displayed no differences in binding to endogenous Skp1, Cul1, or other interacting proteins (Fig. 1) . Identical results were obtained using HeLa cells transiently transfected (to achieve high expression, as in Fig. 1 and in ref. 6 ) or retrovirally infected Despite a plethora of published studies on F-box proteins in eukaryotes, there is no evidence to suggest a role for the N-terminus of F-box proteins in regulating SCF assembly. On the contrary, the literature indicates that Skp1 stably binds the F-box domain and that free F-box proteins are too hydrophobic to exist in the cell in the absence of Skp1. Notably, in contrast to the strict conservation of Ser64 from insects to humans, Ser72 is not conserved in the mouse or lower vertebrates, indicating a non-essential role for this residue.
In conclusion, our data demonstrate that the phosphorylation of Ser72 does not control Skp2 binding to Skp1 or Cul1, has no influence on SCF Skp2 ubiquitin ligase activity, and does not affect the subcellular localization of Skp2. Importantly, two other groups independently reached the same conclusions.
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Materials and Methods
Reagents, antibodies and DNA constructs. LY294002 was obtained from Cell Signaling Technology. FLAG-tagged Skp2 constructs were obtained by subcloning Skp2 wild type and mutants in the pcDNA3 vector. The phospho-specific antibody to phosphorylated Akt1 (Ser473) was from Cell Signaling. Antibodies to Skp2 and p27 were previously described. 13 All other antibodies were described in. 14 (myr-Akt1) did not change the nuclear localization of Skp2 (Fig. 5) .
Thus, although Ser72 appears to regulate Skp2 stability in conjunction with Ser64, 4,5 its phosphorylation status has no influence on SCF Skp2 complex formation, ubiquitin ligase activity, or Skp2 localization.
Our results contrast starkly with the study of Lin et al. 6 which asserts that Skp2 is phosphorylated on Ser72, allowing Skp2 to bind Skp1 and Cul1, thus triggering p27 ubiquitylation. Instead, our data are in agreement with a large body of literature showing that the in vitro ubiquitylation activity of wild type Skp2 does not require the addition of Akt to the reaction (reviewed in refs. [8] [9] [10] . This result also holds true for studies utilizing pre-assembly of the entire wild type SCF Skp2 complex in bacteria, 11, 12 where Skp2 is not phosphorylated. Similarly, Rodier et al. did not observe impaired SCF assembly or decreased activity for Skp2(Ser64/72Ala). 4 Gao et al. 5 and Lin et al. 6 also suggest that phosphorylation of Skp2 on Ser72 (or mutation of Ser72 to Asp, which mimics phosphorylation) induces the relocalization-or retentionof Skp2 in the cytoplasm, an event that, in turn, promotes cell migration via an unknown mechanism. It is unclear whether Skp2 or the entire SCF Skp2 complex is relocalized to the cytoplasm. However, we have never observed differential localization of either Skp2(Ser72Ala) or Skp2(Ser72Asp) compared to wild type Skp2 (Fig. 5 and data not shown) , nor have we observed cytoplasmic Skp2 in cells expressing myr-Akt1 (Fig. 5) . In vitro ubiquitylation assays. In vitro ubiquitylation reactions were performed as previously described. 15 Briefly, ubiquitylation was performed in a volume of 10 µl containing 50 mM Tris pH 7.6, 5 mM MgCl 2 , 0.6 mM DTT, 2 mM ATP, 2 µl in vitro translated unlabelled Skp2, 1.5 ng/µl E1 (Boston Biochem), 10 ng/µl Ubc3, 10 ng/µl Ubc5, 2.5 µg/µl ubiquitin (Sigma), 1 µM ubiquitin aldehyde, 0.1 µl purified, recombinant Cdk2-cyclin E complex, 0.1 µl purified, recombinant Cks1, and 1 µl 35 S-methionine-labelled in vitro translated p27.
